Page 45 - 2021_03-Haematologica-web

Multicenter validation of targeted NGS in CLL
for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
33.Gargis AS, Kalman L, Berry MW, et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol. 2012;30(11):1033-1036.
34. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733-747.
35. Aziz N, Zhao Q, Bry L, et al. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med. 2015;139(4):481-493.
36. Jennings LJ, Arcila ME, Corless C, et al. Guidelines for Validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017;19(3):341-365.
37. Roy S, Coldren C, Karunamurthy A, et al.
Standards and guidelines for validating next- generation sequencing bioinformatics pipelines a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists. J Mol Diagn. 2018;20(1):4-27.
38. Haslam K, Catherwood MA, Dobbin E, Sproul A, Langabeer SE, Mills KI. Inter-labo- ratory evaluation of a next-generation sequencing panel for acute myeloid leukemia. Mol Diagn Ther. 2016;20(5):457- 461.
39.Hirsch B, Endris V, Lassmann S, et al. Multicenter validation of cancer gene panel- based next-generation sequencing for trans- lational research and molecular diagnostics. Virchows Arch. 2018;472(4):557-565.
40. Rossi D, Khiabanian H, Rasi S, et al. Small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations are clinically irrelevant in chronic lymphocytic leukemia. Blood. 2014; 124(21):295.
41. Ahn IE, Underbayev C, Albitar A, et al.
Clonal evolution leading to ibrutinib resist- ance in chronic lymphocytic leukemia. Blood. 2017;129(11):1469-1479.
42. Blombery P, Anderson MA, Gong JN, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342-353.
43.Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286-2294.
44. Tausch E, Close W, Dolnik A, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019;104(9):e434-e437.
45. Malcikova J, Tausch E, Rossi D, et al. ERIC recommendations for TP53 mutation analy- sis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia. 2018;32(5):1070- 1080.
haematologica | 2021; 106(3)
691